In this ancient fable, a farmer and his wife discover that their goose is laying golden eggs. They become so greedy that they slaughter the goose hoping to retrieve the big lump of gold that they assume must be inside her. Instead, they find nothing special. Killing the goose meant no more golden eggs.

The Daraprim Debacle:

The latest example of drug company greed grabbed headlines because it was shameless. A 62-year-old drug called pyrimethamine (Daraprim) is used to treat a potentially life-threatening parasitic infection called toxoplasmosis.

This medicine was originally developed by an acquaintance of ours, Gertrude Elion. She was working for the drug company Burroughs Wellcome at the time. Trudy went on to win the Nobel Prize for her many amazing drug discoveries. She would be turning over in her grave to know what has happened to the compound she developed for treating malaria and the parasite Toxoplasma gondii.

Rights to this very old medication were acquired in August, 2015, by the startup firm Turing Pharmaceuticals. The price shot up from a fairly high $13.50 per tablet to $750 per pill shortly after the drug was acquired by the new company. That brought the cost of treating a case of toxoplasmosis to as much as $73,500, an increase of more than 5,000 percent almost overnight.

This case stood out because the cost of manufacturing is low, estimated at less than $1 a pill. After all, this drug has been around for more than 60 years. Its research and development costs were amortized decades ago. There was no justifiable reason to hike the price so much. Imagine a cup of coffee going from $2.50 to $125 a cup overnight. No one would stand for it.

The media attention and public outcry were so great that eventually the company announced it would roll back the price hike on Daraprim. What that final price will be, however, remains to be seen. Once the media furor dies down, will the price go back to $13.50 a pill or something substantially higher?

The Cycloserine Crisis:

Pyrimethamine isn’t the only old generic drug to have its price boosted suddenly. A medicine for tuberculosis called cycloserine recently jumped over 2,000 percent almost overnight. This medication was first marketed in 1955. The price went from $15 a pill to $360. The drug is used to treat a rare form of multi-drug resistant TB that could pose a public health hazard if not controlled.

Because outraged physicians spoke up, the deal that gave Rodelis Therapeutics rights to the drug were reversed. The nonprofit that now owns the license to cycloserine will reportedly “only” charge $35 per capsule.

Valeant Avarice:

Valeant Pharmaceuticals has seen its stock price skyrocket from a little over $50 a share in 2013 to over $250 a share this year. That’s partly because the company has also jacked up drug prices on some old generic products. Isoproterenol (Isuprel) is a very old drug that is crucial for certain kinds of life-threatening heart rhythm problems. It is also essential when a patient develops serious breathing problems during general anesthesia.

According to the Wall Street Journal, Valeant increased the price of Isuprel by 525 percent to $1,347 a vial. By the way, the New York Times reports that top executives made out very well:

“While other multinational pharmaceutical companies spend well into the double digits as a percentage of sales, Valeant’s 2014 annual report shows that the company spent $246 million on research and development — just 3 percent of sales. Another way to think about that: Valeant paid its five highest-paid executives 1.5 percent of sales, or $123 million, last year.”

Drug Company Greed Overwhelms the Orphan Drug Act:

Historically, generic drugs have been a bargain. But these examples show that just because a drug has lost its patent does not mean it will be inexpensive. This seems to be especially true when it comes to medicine for relatively rare conditions like toxoplasmosis, which can be fatal if untreated. In such cases, company executives may feel entitled to charge what they think the market will bear.

When the Orphan Drug Act was passed by Congress in 1983 it was supposed to encourage drug companies to develop medicines most people assumed would not be profitable. That’s because such drugs treat rare diseases that affect a relatively small number of people. In fact the FDA initially referred to these medications as “significant drugs of limited commercial value.”

In those days, drug companies could not have imagined charging hundreds of dollars for a course of treatment, much less hundreds of thousands. The assumption was that the American public wouldn’t stand for price gouging. An executive within the pharmaceutical industry told us decades ago that if a cure for cancer were developed the company would have to virtually give it away. Otherwise drug company greed would be the undoing of the industry. Other Pharma execs were in agreement, but that was a long time ago.

Congress created incentives so companies would invest in rare diseases for which they might not break even. The government offered substantial tax breaks and in some cases subsidized clinical research. Patent and market exclusivity were also big bonuses for orphan drug development.

Orphan Drugs Now Worth More Than Gold:

Sadly, the original intent of this humanitarian orphan drug initiative has been undermined by drug company greed. Major brand name manufacturers discovered that they could charge whatever they wanted and the public would not complain.

When the hepatitis C drug Sovaldi was marketed, the price was $1,000 a day. A full course of treatment requires 12 weeks of daily dosing.

New melanoma drugs cost unimaginable amounts: treatment with Yervoy (ipilimubab) can run nearly $120,000 while a competitor, Keytruda (pembrolizumab), approaches $150,000 a year.

The FDA has just approved the use of Yervoy and and another immunotherapy drug called Opdivo (nivolumab) together to treat metastatic melanoma. This combination is substantially better than either drug alone. Opdivo costs roughly $150,000 a year. A patient receiving both Opdivo and Yervoy could face a bill of $270,000 a year. Even if insurance would cover this combination, the co-pay could be overwhelming.

The Gouging of Gaucher Patients:

A rare genetic condition called Gaucher’s disease causes untold suffering. Without treatment patients develop cognitive impairment, seizures, broken bones and many other life-threatening complications. A biotech drug that can help control this disorder, Cerdelga, has been reported to cost over $300,000 a year.

Oncologists and infectious disease experts are finally speaking up about the unsustainable costs of drugs. Perhaps it is time for the American public to tell the pharmaceutical industry that the goose is about to stop laying its golden eggs.

We welcome your thoughts about the cost of orphan drugs in the comment section below. You may wish to let your Congressman know how you feel or contact PhRMA, the voice of the pharmaceutical industry. The president and CEO of the Pharmaceutical Research and Manufacturers of America is John. J. Castellani.

16 Thoughts Shared

Beth

VA

October 11, 2015 at 2:45 pm

One of the few ways we really have of “controlling” health care costs, including pharmaceutical cost, is to control our OWN health!!! When nutrition becomes medicine, the pharmaceutical companies will not be able to hold a candle to it and their profits will be significantly reduced.
When we remain dependent on physicians and pharmaceuticals –the unfortunate “way” of American healthcare–we remain VICTIMS of this system!!!
Most, if not all, big/scary disease is treatable and preventable with solid nutrition. Take control!!!
Thank you, People’s Pharmacy for bringing attention to this important issue!!!

goose

holmes beach

October 8, 2015 at 6:28 pm

Hard to fathom such inhumanity toward fellow man in the USA. The lack of caring or concern pertaining to fellow Americans’ health is just unreal! Big Pharma has been allowed to take over and pad the pockets of elected officials. What a sad and embarrassing state of affairs when you have to leave the USA to get treated with real functional medicine offered in other countries!!!

Jessica

Hampton, VA

October 7, 2015 at 6:08 pm

These are just a few of the billions of medicines–both over the counter and prescribed–made by pharmaceutical companies. If each one were just tripled in what remains after manufacture costs are deducted (net) still means hundreds of billions to trillions of earnings. No wonder people are leaning more and more towards Socialism (which would limit the earnings therefore making it more affordable) of medicine. I know this can cause other problems but many of us are at a point of choosing between food and medicine that is needed to survive.

And it’s not just the pharmaceutical companies as with each level between the making of things and the consumer purchasing them adds their own mark up (for example one pharmacy conglomerate is advertising that they will provide a free flu shot for everyone paid for makes me wonder just how much of a profit is on each for them to be able to afford this and still provide a profit to the stock holders).

I shake my head at the greed shown and worry about the future of the human race.

Cindy Black

Seattle, WA

October 7, 2015 at 1:32 am

I’ve commented on this topic before, but seeing this article brings absolute rage bubbling up to the surface once again. To take advantage of sick people, to kick them in the teeth when they’re already down on the ground and basically defenseless, to take advantage of their bad luck just to line one’s already-bulging pockets — well, it’s a crime and it ought to be dealt with as one. If the legal system isn’t up to the task, there is always vigilante justice.

Julie

October 6, 2015 at 4:26 pm

The drug companies are making their drugs so expensive that they are unaffordable to the sick who need the drugs. They are dangling the cure out of reach of many who are suffering and dying because of their greed. The CEO’s instead of getting millions of dollars in bonuses should be getting jail sentences.

We as a society are also at fault for making health care an ultra profitable business unaffordable to many. Instead runaway profits and bonuses, we need to let health care providers and suppliers earn a very good living but not excessive and keep health care non profit. It used to be that the hospitals were non profit organizations here to help and care for people rather than focusing on profit over health.

Penelope

Florida

October 6, 2015 at 3:36 pm

Get Congress to require Medicare to negotiate drugs for Part D, like the VA does and other countries. It sounds like the cheeky owner of Turing actually did the country a favor by waking up people to the seriousness of the problem.

seeSHA

Fl.

October 6, 2015 at 3:30 pm

Notice how this has all come on strong since our wonderful politicians have declared that we cannot get our drugs outside of the United States. Gosh! It makes you think they are in the pocket of the drug companies!

Shirley

Texas

October 6, 2015 at 2:28 pm

I understand that the pharmaceutical companies want to make profits; but, these astronomical price increases are unreasonable. I say “live and let live”, and give people a break by selling drugs at reasonable prices.

MJW

NYC

October 6, 2015 at 12:06 pm

Lars

MA

October 6, 2015 at 10:00 am

The examples you set out are disturbing, particularly since the prices charged in other countries for the same drugs are a fraction of the outrageous prices in the US. However I wonder why there are only two companies named in the article and others are not. Surely they are not the only ones indulging themselves at the expense of consumers.
It would be interesting to your subscribers, listeners and readers to know which companies are responsible for the production/distribution of the other drugs described in the article: Solvadi, Yervoy, Keytruda, Opdivo and Cerdelga.

Ellen

Pittsboro NC

October 6, 2015 at 8:16 am

This is a thoughtfully written article. It exposes just a fragment of the pharmaceutical industry’s avarice and brutality. It is truly hard to imagine how a letter to a congressperson or a note to PhRMA could even cause a blink among the perpetrators (not that it shouldn’t be done). Is there an organized group which is already legally and politically opposing the drug industry? No point in reinventing the wheel, if it’s already rolling.

Lori

NH

October 6, 2015 at 7:47 am

The article on drug prices really hit home. My husband was recently diagnosed with mild to moderate dementia and was put on Aricept and Namenda XR. Namenda XR is a tier 3 drug with no generic and costs $11 per pill. However, I guess we have to count our blessings that he is not on a lot of drugs.

Peace,
Lori

Pat

USA

October 6, 2015 at 7:37 am

This degree of greed is sickening. It’s not just prescription drugs, either. In 2012 I bought a 4 pack of Denture Grip, a temporary denture adhesive/liner, for $19.30.I went to buy another 4 pack recently and it’s now $399.99! I was told that the company had been sold, but that’s all I could find out.

James

Raleigh

October 6, 2015 at 6:05 am

We invite you to share your thoughts with others, but remember that our comment section is a public forum. Please do not use your full first and last name if you want to keep details of your medical history anonymous. A first name and last initial or a pseudonym is acceptable. Advice from other commenters on this website is not a substitute for medical attention. Do not stop any medicine without checking with the prescriber. Stopping medication suddenly could result in serious harm. We expect comments to be civil in tone and language. By commenting, you agree to abide by our commenting policy and website terms & conditions. Comments that do not follow these policies will not be posted.